pBFS Guided rTMS Over Cognitive Control Network for ASD (NCT06255535) | Clinical Trial Compass
RecruitingNot Applicable
pBFS Guided rTMS Over Cognitive Control Network for ASD
China215 participantsStarted 2024-04-01
Plain-language summary
The aim of this trial is to assess the efficacy and safety of precision neuromodulation for alleviating core symptoms in patients with autism spectrum disorder (ASD) who also have intellectual or developmental delay. The neuromodulation will be administered using intermittent theta burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex (DLPFC), guided by personalized Brain Functional Sector (pBFS) technology.
Who can participate
Age range6 Years – 30 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 6-30 years old
* Have the diagnosis of autism spectrum disorder
* ADOS-2 score is higher than the ASD cut-offs
* Comorbid with intelligent disorder, IQ/DQ \< 70
* Primary environmental language is Chinese
* Participant's parents or other legal guardians give informed consent
Exclusion Criteria:
* Genetic Disorders, such as (e.g., Down syndrome, Fragile X syndrome, Rett syndorme), Current or history of severe ADHD, tourette syndrome, psychotic disorders (e.g., schizophrenia, schizoaffective disorder, bipolar disorder)
* Severe self-injury or suicidal behavior exhibited within the past year
* Significant visual, auditory, deafness or motor disability that prevent them from following study procedures
* Current or history diagnosis of epilepsy
* Known severe physical diseases, particularly those affecting the brain
* Metal implantation contradicted by MRI or TMS, such as artificial cardiac pacemakers, stents, cochlear implants
* Respiratory or circulatory conditions increasing sedation risk, such as Apnea syndrome, severe snoring, or other relevant diseases
* All legal guardians are illiterate, unable to read informed documents or complete questionnaires independently
* Received transcranial magnetic stimulation (TMS), transcranial current stimulation (tCS), focused ultrasound (FUS), or other neuromodulation treatment in the last 3 months
* Current participation in other clinical trials